Key result
Transcatheter aortic valve implantation (TAVI) has revolutionized the treatment of severe symptomatic aortic stenosis for patients deemed inoperable or at prohibitively high surgical risk.
This review discusses current and future indications for transcatheter aortic valve implantation (TAVI) in patients with severe symptomatic aortic stenosis.
Answers are grounded in this paper and cite their sources.
Guides TAVI decisions in prohibitive-risk aortic stenosis; leaves open refinement of future indications.
Aortic stenosis (AS) is the most common valvular pathology and its prevalence is expected to increase rapidly in coming decades as a consequence of the increasingly elderly population. Without treatment, severe symptomatic AS has a very poor prognosis with a mortality of 50% at two years. Whilst surgical aortic valve replacement is the gold standard treatment, a significant minority of patients are deemed inoperable and declined surgery due to prohibitively high risk. The advent of transcatheter aortic valve implantation (TAVI) has revolutionised their treatment. In this review, we discuss current indications for TAVI, other applications of this technology and future indications.
No takes yet. Share an insight, caveat, or question.
Ruparelia et al. (2015) conducted a review in Aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement was evaluated. Transcatheter aortic valve implantation (TAVI) has revolutionized the treatment of severe symptomatic aortic stenosis for patients deemed inoperable or at prohibitively high surgical risk.
Synapse has enriched 10 related papers. Consider them for comparative context: